

Supplementary Table 1. Pre-vaccination GMTs for each strain in subjects 6 months to < 9 years of age.

| Strain | QIV (N=2339) | | Licensed TIV (N=582) | | Investigational TIV (N=599) | |
|------------|-----------------|-------------------|-------------------------|-------------------|--------------------------------|-------------------|
| | M | GMT (95% CI) | M | GMT (95% CI) | M | GMT (95% CI) |
| A/H1N1 | 2333 | 40.4 (37.2; 43.9) | 581 | 40.3 (34.2; 47.4) | 599 | 43.4 (36.8; 51.2) |
| A/H3N2 | 2334 | 29.1 (26.9; 31.6) | 579 | 32.5 (27.5; 38.4) | 598 | 30.1 (25.5; 35.5) |
| B/Brisbane | 2337 | 8.2 (7.9; 8.5) | 582 | 8.5 (7.9; 9.2) | 599 | 8.8 (8.1; 9.5) |
| B/Florida | 2336 | 7.5 (7.2; 7.7) | 582 | 7.4 (6.9; 7.9) | 598 | 7.6 (7.1; 8.1) |

Immunogenicity analyses were performed on the per-protocol analysis set. M is the number of subjects with a valid serology result for the specified antigen. Abbreviations: CI, confidence interval; GMT, geometric mean titer; QIV, quadrivalent influenza vaccine; TIV, trivalent influenza vaccine.